Please check your internet connection and try again.
# Hepa-Merz (L-Ornithine L-Aspartate / LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two endogenous amino acids. It serves as a substrate for the urea cycle and stimulates glutamine synthesis in skeletal muscle, effectively lowering serum ammonia levels in patients with impaired hepatic clearance.
## Primary Indications
Treatment of hyperammonemia in patients with acute or chronic liver disease (e.g., hepatic encephalopathy, liver cirrhosis, fatty liver).
## Adult Dosing
* **Oral (Granules):** 1–2 sachets (3g–6g) dissolved in liquid, taken 3 times daily after meals.
* **IV (Infusion):** Up to 4 ampoules (40g) daily in severe cases of hepatic encephalopathy. Administer via slow infusion in a compatible IV solution (e.g., 5% dextrose or normal saline). Do not exceed 5g per hour to prevent infusion-related complications.
## Pediatric Dosing
**Safety and efficacy in children have not been well established.** Use is not routinely recommended unless directed by a pediatric hepatologist or clinical specialist. Dosing is highly individualized based on local institutional protocols.
## Dose Adjustments
* **Renal Impairment:** If serum creatinine is elevated (>3 mg/dL), minimize use or avoid due to risk of accumulation. Monitor renal function closely.
* **Hepatic Impairment:** No specific reduction required, as it is indicated for liver disease; however, monitor for signs of over-infusion if metabolic state is unstable.
## Contraindications
* Severe renal insufficiency (renal failure).
* Hypersensitivity to L-ornithine or L-aspartate.
* History of severe lactic acidosis (case-by-case evaluation required).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain.
* **Rare:** Injection site reactions, pruritus, transient elevation of BUN/creatinine, muscle cramps, or dizziness.
## Key Drug Interactions
* **No major clinical drug-drug interactions documented:** Unlike medications metabolized via CYP450, LOLA acts through metabolic pathways involving the urea cycle.
* **Additive effects:** If used with lactulose, effectiveness may be synergistic, but it does not replace the standard of care for acute HE.
## Monitoring
* **Serum Ammonia:** Baseline and serial monitoring to assess therapeutic response.
* **Renal Function:** Electrolytes and BUN/Creatinine, especially in IV administration.
* **Metabolic State:** Monitor for clinical improvement in neurologic signs (West Haven Criteria) or mental status.
## Clinical Pearls
* **Not a Monotherapy:** LOLA is an adjunct to, not a replacement for, standard hepatic encephalopathy management (lactulose and rifaximin).
* **IV Administration:** When administering intravenously, ensure the solution remains clear. Do not mix with other medications in the same infusion bag.
* **Oral Absorption:** Granules should be dissolved in a large glass of water or juice to ensure solubility and gastrointestinal comfort.
***
**Disclaimer:** This information is for educational purposes and does not substitute for clinical judgment. Dosing protocols may vary by hospital and region. Always consult the latest local package insert or institutional formulary before prescribing or administering medication.
